Safety of anti-tumor necrosis factor agents in psoriatic arthritis – an update

Bibliography

• Cantini F, Niccoli L, Nannini C, et al. Psoriatic arthritis: a systematic review. Int J Rheum Dis 2010;13(4):300-17
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E. Psoriatic arthritis: imaging techniques. Reumatismo 2012;64:99-106
   PubMedGoogle Scholar
• Palazzi C, D'Angelo S, Lubrano E, et al. New insights in occult psoriasi arthritis. J Rheumatol Suppl 2012;89:22-3
   PubMedGoogle Scholar
• Palazzi C, Lubrano E, D'Angelo S, et al. Beyond early diagnosis: occult psoriatic arthritis. J Rheumatol 2010;37:1556-8
   PubMed Web of Science ®Google Scholar
• Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guidelines Committee. Systematic review of treatments of psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Palazzi C, Olivieri I. Psoriatic arthritis: treatment strategies using biologic agents. Reumatismo 2012;64:113-21
   PubMedGoogle Scholar
• Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012;64:107-12
   PubMedGoogle Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
   PubMed Web of Science ®Google Scholar
• Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005;17:406-12
   PubMed Web of Science ®Google Scholar
• Punzi L, Podswiadek M, Sfriso P, et al. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 2007;6:524-8
   PubMed Web of Science ®Google Scholar
• Cordiali-Fei P, Trento E, D’Agosto G, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokinesin in the sera and skin lesions. Ann NY Acad Sci 2007;1110:578-89
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, et al. Tumor necrosis factor antagonists: different kinetic and/or mechanisms of action may explain differences in the risks for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010;2:817-33
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Palazzi C, Cantini F, et al. Etanercept in spondyloarthropathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011;29:865-70
   PubMed Web of Science ®Google Scholar
• Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev 2013;12:691-3
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DPM, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trial. J Rheumatol 2008;35:883-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
   PubMed Web of Science ®Google Scholar
• Fénix-Caballero S, Alegre-Del Rey EJ, Castaño-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013;38(4):286-93
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72(11):1777-85
   PubMed Web of Science ®Google Scholar
• Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 2011;38:1355-62
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:697-705
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gülfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9
   PubMed Web of Science ®Google Scholar
• Peluso R, Cafaro G, Di Minno A, et al. Side effects of TNF-alpha blockers in patients with psoriatic arthritis: evidence from literature studies. Clin Rheumatol 2013;32:743-53
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, et al. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
   PubMed Web of Science ®Google Scholar
• Lioté H, Lioté F. Role for interferon-gamma release assays in latent tuberculosis screening before TNF-alpha antagonist therapy. Joint Bone Spine 2011;78:352-7
   PubMed Web of Science ®Google Scholar
• Sanduzzi A, Bocchino M, Atteno M, et al. Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-alpha blockers for psoriatic arthritis. J Rheumatol Suppl 2012;89:82-5
   PubMedGoogle Scholar
• Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Danish Society for Gastroenterology. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59:C4480
   PubMed Web of Science ®Google Scholar
• Klein M, Jarosová K, Forejtová S, et al. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 2013;31:111-17
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011;90:359-71
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Reumatol 2012;8:348-57
   PubMed Web of Science ®Google Scholar
• Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217-19
   PubMed Web of Science ®Google Scholar
• Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30:700-6
   PubMed Web of Science ®Google Scholar
• Puig L, Morales-Múnera CE, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012;225:14-17
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. On behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894):780-9
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Béné J, et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 2012;7:e48991
   PubMed Web of Science ®Google Scholar
• Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumor necrosis factor therapy, and risk of malignant melanoma: nationwide population bases prospective cohort study from Sweden. BMJ 2013;346:f1939
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapyana narrowbandUV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26(Suppl 3):22-31
   PubMed Web of Science ®Google Scholar
• Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012;51(Suppl 6):vi37-43
   PubMed Web of Science ®Google Scholar